The LYMPH Trial - Comparing Microsurgical With Conservative Treatment of Chronic Breast Cancer Associated Lymphedema: Study Protocol of a Pragmatic Randomized International Multicentre Superiority Trial
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 280
- 试验地点
- 71
- 主要终点
- Change in Quality of Life Questionnaire (Lymph-ICF-UL)
研究概览
简要总结
The aim of this study is to test whether lymphatic surgery provides better QoL (assessed with the Lymph-ICF-UL, (Lymphedema Functioning Disability and health questionnaire for upper limb lymphedema)) 15 months after randomization (and therefore about one year after surgery) compared to conservative treatment only for patients with chronic lymphedema (LE)
详细描述
To date, conservative complex physical decongestion therapy (CDT) is the gold standard for BCRL (breast cancer related lymphedema) and includes manual lymphatic drainage, local compression with bandages and garments, physical exercises and meticulous skin care. It is, however, too often ineffective to prevent stage progression in curing BCRL and purely symptomatic. Lymphovenous anastomosis (LVA) and vascularized lymph node transfer (VLNT) are two surgical techniques that, in contrast to CDT, are able to actually address the underlying causes and eventually restore the lymphatic drainage. LVA achieves this by creating numerous bypasses between lymphatic vessels and venules allowing the drainage of excessive fluid within the subcutaneous tissues into the venous system, while VLNT usually brings functioning lymph nodes to an area devoid of lymph nodes or with dysfunctional lymph nodes, thus enabling the spontaneous development of new lymphatic pathways. Both techniques have shown very promising results with low complication rates and improved Quality of Life (QoL) for the patients. However, no multicentric randomized controlled trial (RCT) has yet prospectively evaluated the superiority of these surgical techniques over CDT alone, limiting patient's access to most effective treatment available. Requests for cost reimbursement must still be submitted to insurance companies in most countries and are often rejected, thus delaying surgical treatment and resulting in prolonged suffering of affected patients. This is untenable seeing as affected patients suffer from a heavy physical, psychological and financial burden. This pragmatic, randomized, multicenter trial aims to establish a solid scientific basis assessing the superiority of surgical treatment over CDT alone.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent.
- •Patients ≥ 18 years of age.
- •Former diagnosis of breast cancer.
- •Clinical diagnosis of chronic Breast Cancer-Related Lymphedema (BCRL) (persisting for more than 3 months) classified as ≥ Stage 1, according to ISL.
- •Minimum of 3 months Conservative Complex Physical Decongestion Therapy.
- •Ability to complete the QoL questionnaires.
- •Willingness to undergo surgery.
排除标准
- •No indication for lymphatic surgery according to clinical judgment of the treating surgeon (individual reasons will be specifically documented).
- •Primary congenital Lymphedema or non-BCRL.
- •Previous surgical BCRL treatment on the side intended for intervention.
研究组 & 干预措施
Group A : Surgical Group
According to the pragmatic study design, neither the diagnostic workup nor the surgery will be standardized in order to offer surgeons considerable leeway on how to perform lymphatic surgery, which resembles the flexibility in usual care. The key aspects of the preoperative workup and the surgery including the number of LVAs (Lymphovenous Anastomosis), harvesting of lymph nodes ("donor site"), time of surgery, and practical details will be registered.
干预措施: Surgical Intervention (Procedure)
Group B: Conservative Complex Physical Decongestion Therapy (control group)
CDT (Conservative Complex Physical Decongestion Therapy) will be performed as in usual care, following the pragmatic study design. The key aspects like frequency of lymphatic drainage, time when lymphatic drainage is performed and time and class of compressive garments are used will be documented. CDT incorporates two stages of treatment. The first treatment phase (intensive phase) entails skincare, MLD (manual lymphatic drainage), exercises aimed at improvement of mobility/range of motion in the shoulder, elbow or wrist joints, and compression therapy through bandaging. Most patients undergo this phase shortly after the diagnosis of LE. CDT in the second phase (maintenance phase) aims to maintain the achieved limb volume/ circumference reduction through compression with therapeutic elastic compression garment for the arm. Skincare, mobility exercises and MLD is continued in this phase if needed
干预措施: Conservative Complex Physical Decongestion Therapy (Procedure)
结局指标
主要结局
Change in Quality of Life Questionnaire (Lymph-ICF-UL)
时间窗: two time assessment at baseline and 15 month after randomization
The LYMPH-ICF-UL-Questionnaire (Lymphedema Functioning Disability and health questionnaire for upper limb lymphedema) is a widely used, rigorously developed, and validated patient-reported outcome (PRO) instrument for chronic breast cancer-related lymphedema. It assesses the impairments in function, activity limitations and participation restrictions of patients with upper limb lymphedema (LE). Consisting of 29 items (questions) across five different domains, each item is scored on a VAS (visual analog scale) ranging from 0 to 10. The total score on the LYMPH-ICF is equal to the sum of the item scores divided by the total number of answered items. A higher score on the Lymph-ICF indicates a greater impact on the functioning in daily life related to upper limb LE. This questionnaire helps determine if lymphatic surgery improves quality of life and patient satisfaction compared to conservative therapy.
次要结局
- Change in Quality of Life Questionnaire (Lymph-ICF-UL)(13 time assessment up to 10 years after randomization)
- Assessment of arm volume(15 time assessment up to 10 years after randomization)
- Assessment of the frequency of lymphatic drainage(15 time assessment up to 10 years after randomization)
- Change in Quality of Life Questionnaire (LYMPH-Q)(15 time assessment up to 10 years after randomization)
- Change in Quality of Life Questionnaire (EuroQol EQ-5D-5L)(15 time assessment up to 10 years after randomization)
- Change in Pain score (visual analog scale)(7 time assessment up to 2 years after randomization)
- Assessment of (serious) adverse events(7 time assessment up to 2 years after randomization)
- Assessment of surgical complications(7 time assessment up to 2 years after randomization)
- Assessment of the burden on patients(9 time assessment up to 10 years after randomization)
- Assessment of the economics (for Switzerland)(9 time assessment up to 10 years after randomization)
- Assessment of lymphangitic events (erysipelas)(7 time assessment up to 2 years after randomization)
